Lilly Pharma collaborates with Breast Cancer Advocacy Organizations, to educate people about early-stage Breast cancer and recurrence

0 67

The American pharmaceutical firm, Eli Lilly and Company, on Wednesday, launched a new education campaign in collaboration with, to recognize the need for more education about breast cancer recurrence. The campaign aims to educate, support, connect, and empower people diagnosed with early breast cancer (EBC) that has a high risk of recurrence.

According to the American Cancer Society, more than 290,650 women and 2,710 men are expected to be diagnosed with breast cancer in the U.S. in 2022. 

“When people are diagnosed with early breast cancer, the initial focus is understandably on selecting and undergoing treatment that will prevent or delay cancer recurrence. However, the risk of developing recurrence may be difficult to comprehend and patients can benefit from additional resources to help understand or augment the information provided by their doctors,”

Stacy Moulder, M.D., senior medical director of Lilly Oncology

Dr. Moulder continued, “This initiative provides patients with comprehensive information on the factors that may affect the risk of breast cancer recurrence. Lilly’s collaboration with advocacy organizations, each of which play a vital role in the breast cancer community, will drive the conversation about risk of breast cancer recurrence further and enable patients to have more informed, proactive discussions with their doctors.”

Early-stage breast cancer is commonly viewed as treatable and survivable in resources. Most people, however, are at some risk of recurrence, and it’s vital to identify individual risk factors. The patients diagnosed with the most prevalent subtype of EBC, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative, are the focus of this new campaign (HER2-).

“Too often, the risk of breast cancer coming back or progressing to metastatic disease is not part of the care team discussion as people navigate diagnosis, treatment, and care. We believe patients benefit from open conversations about breast cancer recurrence,” said Jean Sachs, CEO, Living Beyond Breast Cancer (LBBC). “LBBC is proud to work alongside, For the Breast of Us, and Susan G. Komen to collaborate with Lilly in launching this educational campaign.”

The initiative offers educational materials and other tools to help patients with HR+, HER2- EBC and their caregivers better understand the disease’s implications, including the risk of recurrence. The campaign includes a digital fact sheet, a patient conversation guide, and an infographic that explain the clinical factors linked to a higher risk of breast cancer recurrence and provides tools for treatment planning in collaboration with a care team.

See the tweet:

Leave A Reply

Your email address will not be published.